WO2003082244A3 - Hfa-suspensionsformulierungen eines anhydrats - Google Patents

Hfa-suspensionsformulierungen eines anhydrats Download PDF

Info

Publication number
WO2003082244A3
WO2003082244A3 PCT/EP2003/002899 EP0302899W WO03082244A3 WO 2003082244 A3 WO2003082244 A3 WO 2003082244A3 EP 0302899 W EP0302899 W EP 0302899W WO 03082244 A3 WO03082244 A3 WO 03082244A3
Authority
WO
WIPO (PCT)
Prior art keywords
anhydrate
hfa
suspension formulation
azoniatricyclo
hydroxydi
Prior art date
Application number
PCT/EP2003/002899
Other languages
English (en)
French (fr)
Other versions
WO2003082244A2 (de
Inventor
Christel Schmelzer
Original Assignee
Boehringer Ingelheim Pharma
Christel Schmelzer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200401159A priority Critical patent/EA008610B1/ru
Priority to EP03717219A priority patent/EP1492498A2/de
Application filed by Boehringer Ingelheim Pharma, Christel Schmelzer filed Critical Boehringer Ingelheim Pharma
Priority to UA20041008758A priority patent/UA79776C2/uk
Priority to CA2479638A priority patent/CA2479638C/en
Priority to BR0308709-3A priority patent/BR0308709A/pt
Priority to IL16369603A priority patent/IL163696A0/xx
Priority to AU2003221509A priority patent/AU2003221509B2/en
Priority to MXPA04009338A priority patent/MXPA04009338A/es
Priority to NZ536030A priority patent/NZ536030A/en
Priority to KR1020047015174A priority patent/KR101005717B1/ko
Priority to JP2003579782A priority patent/JP5147158B2/ja
Priority to MEP-2008-473A priority patent/ME00246B/de
Priority to YU86004A priority patent/RS52481B/en
Publication of WO2003082244A2 publication Critical patent/WO2003082244A2/de
Publication of WO2003082244A3 publication Critical patent/WO2003082244A3/de
Priority to ZA2004/05637A priority patent/ZA200405637B/en
Priority to NO20044004A priority patent/NO20044004L/no
Priority to HR20040890A priority patent/HRP20040890A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Die Erfindung betrifft Treibgasformulierungen enthaltend Suspensionen des kristallinen Anhydrats von (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromid.
PCT/EP2003/002899 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats WO2003082244A2 (de)

Priority Applications (16)

Application Number Priority Date Filing Date Title
YU86004A RS52481B (en) 2002-03-28 2003-03-20 FORMULATION OF HFA-SUSPENSION CONTAINING ANHYDRATE
MXPA04009338A MXPA04009338A (es) 2002-03-28 2003-03-20 Formulaciones de un anhidrato en suspension con hfa.
UA20041008758A UA79776C2 (en) 2002-03-28 2003-03-20 Hfa-suspension formulation of crystalline tiotropium bromide anhydrate and use thereof
CA2479638A CA2479638C (en) 2002-03-28 2003-03-20 Hfa-suspension formulations of crystalline tiotropium bromide anhydrate
BR0308709-3A BR0308709A (pt) 2002-03-28 2003-03-20 Formulações em suspensão de hfa de um anidrato
IL16369603A IL163696A0 (en) 2002-03-28 2003-03-20 Hfa-suspension formulation of an anhydrate
AU2003221509A AU2003221509B2 (en) 2002-03-28 2003-03-20 HFA-suspension formulation of an anhydrate
EA200401159A EA008610B1 (ru) 2002-03-28 2003-03-20 Суспензионные препараты на основе кристаллического ангидрата тиотропийбромида
NZ536030A NZ536030A (en) 2002-03-28 2003-03-20 HFA-suspension formulation of crystalline tiotropium bromide anhydrate
JP2003579782A JP5147158B2 (ja) 2002-03-28 2003-03-20 無水物のｈｆａ懸濁製剤
KR1020047015174A KR101005717B1 (ko) 2002-03-28 2003-03-20 무수물의 ｈｆａ-현탁 제형
MEP-2008-473A ME00246B (de) 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats
EP03717219A EP1492498A2 (de) 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats
ZA2004/05637A ZA200405637B (en) 2002-03-28 2004-07-15 Hfa-suspension formulation of an anhydrate
NO20044004A NO20044004L (no) 2002-03-28 2004-09-23 HFA-Suspensjonsformulering av et anhydrat
HR20040890A HRP20040890A2 (en) 2002-03-28 2004-09-27 Hfa-suspension formulation of an anhydrate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10214264.5 2002-03-28
DE10214264A DE10214264A1 (de) 2002-03-28 2002-03-28 HFA-Suspensionsformulierungen eines Anhydrats

Publications (2)

Publication Number Publication Date
WO2003082244A2 WO2003082244A2 (de) 2003-10-09
WO2003082244A3 true WO2003082244A3 (de) 2004-02-05

Family

ID=28050990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/002899 WO2003082244A2 (de) 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats

Country Status (21)

Country Link
EP (1) EP1492498A2 (de)
JP (1) JP5147158B2 (de)
KR (1) KR101005717B1 (de)
CN (1) CN1642525A (de)
AU (1) AU2003221509B2 (de)
BR (1) BR0308709A (de)
CA (1) CA2479638C (de)
DE (1) DE10214264A1 (de)
EA (1) EA008610B1 (de)
EC (1) ECSP045322A (de)
HR (1) HRP20040890A2 (de)
IL (1) IL163696A0 (de)
ME (1) ME00246B (de)
MX (1) MXPA04009338A (de)
NO (1) NO20044004L (de)
NZ (1) NZ536030A (de)
PL (1) PL371295A1 (de)
RS (1) RS52481B (de)
UA (1) UA79776C2 (de)
WO (1) WO2003082244A2 (de)
ZA (1) ZA200405637B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1881980B1 (de) * 2005-05-02 2012-08-22 Boehringer Ingelheim International GmbH Neue kristalline formen von tiotropiumbromid
CA2606552A1 (en) * 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Crystalline forms of tiotropium bromide
US9463161B2 (en) * 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
US20190374519A1 (en) * 2016-09-19 2019-12-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418716A1 (de) * 1989-09-16 1991-03-27 Boehringer Ingelheim Kg Neue Thienylcarbonsäureester von Aminoalkoholen, ihre Quaternierungsprodukte sowie die Herstellung und Verwendung dieser Verbindungen
WO2000007567A1 (de) * 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
WO2001078741A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and budesonide
WO2001078743A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and mometasone
WO2001078739A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and fluticasone proprionate
WO2001078736A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and rofleponide
WO2002036163A2 (de) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen aus tiotropiumsalzen und antihistaminika zur therapie von atemwegserkrankungen
WO2002069944A2 (de) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
WO2002074034A2 (de) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholinergika und endothelinantagonisten

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418716A1 (de) * 1989-09-16 1991-03-27 Boehringer Ingelheim Kg Neue Thienylcarbonsäureester von Aminoalkoholen, ihre Quaternierungsprodukte sowie die Herstellung und Verwendung dieser Verbindungen
WO2000007567A1 (de) * 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
WO2001078741A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and budesonide
WO2001078743A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and mometasone
WO2001078739A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and fluticasone proprionate
WO2001078736A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and rofleponide
WO2002036163A2 (de) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen aus tiotropiumsalzen und antihistaminika zur therapie von atemwegserkrankungen
WO2002069944A2 (de) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
WO2002074034A2 (de) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholinergika und endothelinantagonisten

Also Published As

Publication number Publication date
CA2479638C (en) 2011-01-04
WO2003082244A2 (de) 2003-10-09
HRP20040890A2 (en) 2005-06-30
NZ536030A (en) 2006-07-28
PL371295A1 (en) 2005-06-13
EA200401159A1 (ru) 2005-04-28
UA79776C2 (en) 2007-07-25
NO20044004L (no) 2004-10-05
AU2003221509B2 (en) 2008-01-24
JP2005527550A (ja) 2005-09-15
IL163696A0 (en) 2005-12-18
MEP47308A (en) 2011-02-10
ECSP045322A (es) 2005-01-28
DE10214264A1 (de) 2003-10-16
ZA200405637B (en) 2005-07-27
EP1492498A2 (de) 2005-01-05
KR20040098022A (ko) 2004-11-18
AU2003221509A1 (en) 2003-10-13
CA2479638A1 (en) 2003-10-09
MXPA04009338A (es) 2005-01-25
JP5147158B2 (ja) 2013-02-20
EA008610B1 (ru) 2007-06-29
ME00246B (de) 2011-05-10
RS52481B (en) 2013-02-28
KR101005717B1 (ko) 2011-01-05
YU86004A (sh) 2006-08-17
CN1642525A (zh) 2005-07-20
BR0308709A (pt) 2005-01-04

Similar Documents

Publication Publication Date Title
YU50903A (sh) Postupak za pripremanje antiholinergikuma,tiotropijumbromida
TW200617007A (en) Crystalline anticholinergic and its use for preparing a pharmaceutical composition
YU27303A (sh) Kristalni monohidrat, postupak za njegovo pripremanje i njegova primena za pripremanje leka
EA200401142A1 (ru) Микронизированный кристаллический тиотропийбромид
CY1105543T1 (el) Σκευασματα εναιωρηματων με hfa που περιεχουν αντιχολινεργικο
WO2002072095A3 (de) Tiotropiumsalzen zur behandlung von inflammatorischen erkrankungen
BE2011C028I2 (en) Macrocyclic analogs and methods of their use and preparation
CA2175372A1 (en) Novel 9-hydroxy-pyrido[1,2-a]pyrimidin-4-one ether derivatives
AU2190797A (en) Buccal, non-polar spray or capsule
WO2001027111A3 (de) Bicyclische imidazo-3-yl-aminderivate
WO2003082244A3 (de) Hfa-suspensionsformulierungen eines anhydrats
WO2004000840A3 (en) Quinuclidine derivatives and pharmaceutical compositions containing the same
WO2001027110A3 (de) Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate
MXPA04009162A (es) Derivados de piperidina u 8-aza-biciclo[3.2.1]oct-3-ilo empleados como moduladores de actividad del receptor de quimiocina (especialmente ccr5).
WO2003082855A1 (fr) Agent anti-inflammatoire
IE830822L (en) IMIDAZO £1,2-c| PYRAZOLO £3,4-e| PYRIMIDINES
CA2339528A1 (en) Hexahydropyrazolo[4,3-c]pyridine metabolites
CA2306883A1 (en) Fast-dissolving pharmaceutical composition comprising as-3201
EP0638569A4 (de) Bicyclische stickstoffverbindungen.
WO2000034245A3 (en) Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase
YU60800A (sh) KRISTALNI OBLICI 1S-(1α(2S*,3R*),9α)-6,10-DIOKSO-N-(2- ETOKSI-5-OKSO-TETRAHIDRO-3-FURANIL)-9-(((1-IZOHINOLINIL) KARBONIL)-AMINO)OKTAHIDRO-6H-PIRIDAZINO(1,2-a) (1,2)DIAZEPIM -1 -KARBOKSAMIDA
AU2002217556A1 (en) Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds
AU2003206759A1 (en) Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-860/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REEP Request for entry into the european phase

Ref document number: 2003717219

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003717219

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/05637

Country of ref document: ZA

Ref document number: 200405637

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 163696

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2600/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003579782

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2479638

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047015174

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009338

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: P20040890A

Country of ref document: HR

Ref document number: 1-2004-501524

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 20038072475

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200401159

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2003221509

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 536030

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1200401126

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 20040406

Country of ref document: UZ

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047015174

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2003717219

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2003221509

Country of ref document: AU

Date of ref document: 20030320

Kind code of ref document: B